In the long human negotiation between medicine and desire, a new study has surfaced a telling tension: more than one million Americans are taking GLP-1 drugs — designed for diabetes and obesity — without any documented medical condition to justify the prescription. The finding, drawn from prescription and health records, arrives against a backdrop of persistent drug shortages that have left patients with genuine diagnoses waiting months for access. It is a moment that asks an old question in a new form: when a powerful tool becomes culturally coveted, how does a society decide who deserves it?
Over 1 Million Americans Taking GLP-1 Drugs Without Medical Necessity
A million people taking medications designed for conditions they don't have
Mark
So the headline is that a million people are taking these drugs without medical reason. But what does that actually mean? Are their doctors just handing out prescriptions to anyone who asks?
Mimi
The research doesn't tell us the doctors' reasoning, which is important. Off-label prescribing is legal and sometimes the right call. A doctor might have clinical reasons for prescribing a GLP-1 drug to someone without diabetes or obesity. But the scale here—a million people—suggests it's not just isolated thoughtful decisions. It's a pattern.
Luke
Right, and we should be careful about the language. The study identified people without "apparent medical reason." That's different from saying there was no reason. We don't know what the doctors were thinking or what their patients' actual health situations were. The study is looking at records, not at clinical judgment.
Mark
Fair point. But if supply is tight and people with diabetes are waiting months for prescriptions, doesn't it matter whether that million includes people who just want to lose weight for cosmetic reasons?
Mimi
That's the real tension. These drugs work. They suppress appetite effectively. So there's demand from people without medical conditions. And if supply is limited—which it is—then every prescription that goes to someone without documented medical need is a prescription not going to someone with diabetes or severe obesity.
Luke
But we don't actually know from this study how much of the shortage is caused by off-label use versus other factors—manufacturing capacity, insurance denials, hoarding, price. The study documents the off-label use. It doesn't prove that's why people with diabetes can't get the drug.
Mark
So what should happen? Should doctors stop prescribing these drugs off-label?
Mimi
That's the question regulators and medical societies are going to have to answer. You can't just ban off-label prescribing—it's sometimes the right thing to do. But you might need clearer guidance about when it's appropriate, and better tracking of how these drugs are actually being used.
Luke
And honestly, we still don't know enough about the long-term effects of these drugs in people without diabetes or obesity. That's another reason to be cautious about widespread off-label use. The safety profile in the intended population is one thing. In a million other people? We're still learning.
The Pulse
- More than one million Americans are using GLP-1 drugs like Ozempic with no documented diagnosis of diabetes, obesity, or any other condition these medications are designed to treat.
- The urgency sharpens because supply has been strained since 2023 — patients with type 2 diabetes and documented obesity have faced rationing, long waits, and outright shortages while off-label use quietly consumed a significant share of available stock.
- Off-label prescribing is legal, but the sheer scale of this pattern suggests something beyond individual clinical judgment — a systemic drift in how these medications are being sought, prescribed, and distributed.
- Safety, cost, and equity concerns are converging: powerful drugs used outside their intended populations carry unknown risks, insurance coverage questions multiply, and healthcare resources may be flowing away from those with the greatest medical need.
- The findings are now pressing regulators, insurers, and medical societies toward a reckoning — whether through tighter prescribing guidance, revised coverage policies, or new oversight mechanisms capable of catching patterns this large.
In the long human negotiation between medicine and desire, a new study has surfaced a telling tension: more than one million Americans are taking GLP-1 drugs — designed for diabetes and obesity — without any documented medical condition to justify the prescription. The finding, drawn from prescription and health records, arrives against a backdrop of persistent drug shortages that have left patients with genuine diagnoses waiting months for access. It is a moment that asks an old question in a new form: when a powerful tool becomes culturally coveted, how does a society decide who deserves it?
Researchers analyzing prescription and health records have documented something striking: more than a million Americans are taking GLP-1 drugs — medications developed for type 2 diabetes and severe obesity — without any documented condition that would justify the prescription. They have no diabetes diagnosis, no obesity diagnosis, no recognized medical reason. They are, by the study's measure, using these drugs outside the established medical framework.
The scale matters because context is everything. GLP-1 medications have been in short supply since demand surged in 2023 and 2024. Patients with diabetes have struggled to fill prescriptions. People with documented obesity have waited months. Pharmacies have rationed. Against that reality, a million off-label users represent not just a clinical curiosity but a question of who gets access and who goes without.
Off-label prescribing is legal — physicians have broad authority to prescribe approved drugs for conditions beyond their labeled use — but the research points to a pattern rather than isolated judgment calls. That distinction matters to regulators, insurers, and medical societies now weighing their response.
The implications branch in several directions at once: access for those with genuine need, safety risks for those using powerful medications outside their intended purpose, and cost questions about whether healthcare resources are being appropriately directed. Perhaps most quietly significant is what the findings reveal about oversight — that current systems were not designed to catch a pattern this large.
What follows remains unwritten. The study may reshape prescribing standards, tighten insurance coverage, or prompt the FDA to reconsider how these drugs are positioned in American medicine. For now, it has done the essential first thing: made the invisible visible.
Researchers have documented a striking pattern in American medicine: more than a million people are taking GLP-1 drugs—the same medications prescribed for diabetes and obesity—without any documented medical condition that would justify the prescription. The finding, emerging from new analysis of prescription and health records, raises urgent questions about how these powerful medications are being distributed and who gets access to them.
GLP-1 receptor agonists, a class of drugs that includes Ozempic and similar compounds, were developed to help people manage type 2 diabetes and severe obesity. The medications work by slowing digestion and signaling fullness to the brain, effects that have made them extraordinarily popular in recent years. But the new research suggests that a substantial portion of people taking these drugs have no diabetes diagnosis, no obesity diagnosis, and no other medical condition typically treated with GLP-1 therapy. They are taking them, in other words, for reasons that fall outside the established medical framework.
The scale of this off-label use is difficult to overstate. One million people represents a significant share of the total GLP-1 user population in the United States. It also represents a significant share of the total supply of these medications, which have been in short supply since demand exploded in 2023 and 2024. Patients with type 2 diabetes have reported difficulty obtaining prescriptions. People with documented obesity have faced months-long waits. Pharmacies have rationed supplies. Against this backdrop, the discovery that over a million people are using these drugs without apparent medical justification takes on a different weight.
The research does not specify exactly who these users are or why their doctors prescribed the medications. Off-label prescribing is legal in the United States, and doctors have broad authority to prescribe approved drugs for conditions other than those listed on the label. A physician can prescribe a diabetes drug to someone without diabetes if they believe it will help that patient. But the new findings suggest a pattern rather than isolated cases—a systematic use of these medications outside their established medical purpose.
The implications ripple outward in several directions. There is the question of access: if supply is limited and some of that supply is going to people without documented medical need, then people with documented need are going without. There is the question of safety: these are powerful medications with side effects, and using them in people without the conditions they were designed to treat introduces unknown risks. There is the question of cost: GLP-1 drugs are expensive, and insurance coverage varies widely. If people without medical justification are obtaining these drugs, questions arise about who is paying and whether that represents appropriate use of healthcare resources.
The research also highlights a gap in how American medicine monitors prescription practices. Doctors prescribe off-label regularly, and it is often appropriate. But the scale of GLP-1 off-label use—over a million people—suggests that current oversight mechanisms may not be catching patterns that warrant attention. Regulatory bodies and medical organizations may need to develop clearer guidance about appropriate use, or at minimum, better systems for tracking how these medications are actually being prescribed.
What happens next remains unclear. The findings may prompt conversations among medical societies about prescribing standards. They may lead insurers to tighten coverage policies. They may influence how the Food and Drug Administration thinks about these drugs and their place in the American medicine cabinet. For now, the research simply documents a fact: millions of Americans are taking medications designed for specific medical conditions without those conditions. The question of what that means, and what should be done about it, is still being written.
Want the full story?
Read the original at The New York Times ↗
Health & Medicine